Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 0.70% and Operating profit at -9.35% over the last 5 years
2
Negative results in Mar 26
3
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 1,220 Million (Small Cap)
43.00
NA
2.16%
-0.41
4.70%
0.66
Revenue and Profits:
Net Sales:
85 Million
(Quarterly Results - Jun 2026)
Net Profit:
10 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.51%
0%
-2.51%
6 Months
4.2%
0%
4.2%
1 Year
-13.55%
0%
-13.55%
2 Years
12.0%
0%
12.0%
3 Years
-23.4%
0%
-23.4%
4 Years
-35.55%
0%
-35.55%
5 Years
-44.27%
0%
-44.27%
Beijing Scitop Bio-Tech Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.70%
EBIT Growth (5y)
-9.35%
EBIT to Interest (avg)
78.74
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.51
Sales to Capital Employed (avg)
0.18
Tax Ratio
6.82%
Dividend Payout Ratio
27.88%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.43%
ROE (avg)
7.69%
Valuation key factors
Factor
Value
P/E Ratio
43
Industry P/E
Price to Book Value
2.02
EV to EBIT
45.96
EV to EBITDA
32.91
EV to Capital Employed
2.74
EV to Sales
8.00
PEG Ratio
NA
Dividend Yield
1.05%
ROCE (Latest)
5.95%
ROE (Latest)
4.70%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
84.50
85.70
-1.40%
Operating Profit (PBDIT) excl Other Income
15.00
25.40
-40.94%
Interest
0.00
0.00
Exceptional Items
1.50
0.60
150.00%
Consolidate Net Profit
10.10
20.90
-51.67%
Operating Profit Margin (Excl OI)
51.50%
196.50%
-14.50%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is -1.40% vs 8.48% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is -51.67% vs -16.40% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
363.40
300.40
20.97%
Operating Profit (PBDIT) excl Other Income
107.60
97.40
10.47%
Interest
0.20
0.30
-33.33%
Exceptional Items
1.60
2.00
-20.00%
Consolidate Net Profit
94.50
94.40
0.11%
Operating Profit Margin (Excl OI)
201.50%
234.80%
-3.33%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 20.97% vs 1.04% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 0.11% vs 0.96% in Dec 2024
About Beijing Scitop Bio-Tech Co., Ltd. 
Beijing Scitop Bio-Tech Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






